Mr. Casamento was President and CEO of Osteologix from October 2004 until April, 2007. Originally a private company founded in Copenhagen, Denmark, during his 29 months at Osteologix, Mr. Casamento commenced operations in the US, completed a financing with Rodman & Renshaw and Roth Capital Partners, took the company public, completed pre-clinical trials on the company's lead product, completed phase I, initiated phase II clinical trials, and had the company granted a European patent for its lead product while gaining recognition on Wall Street as a viable public company. Osteologix was Mr. Casamento's fourth start up company, all of which completed IPOs during his tenure.

During his career, Mr. Casamento has held a number of marketing, sales, finance and business development positions with Sandoz, Hoffmann-LaRoche, Johnson & Johnson and American Hospital Supply Corporation where he was Vice President of Business Development and Strategic Planning for the Critical Care Division.

He was Senior Vice President & General Manager for Pharmaceuticals and Biochemicals at Genzyme from 1985 through 1989 during which time Genzyme was taken public. In 1989 he co-founded and later took public, Interneuron Pharmaceuticals (Indevus) which eventually reached a $1.6 billion valuation. In 1993 Mr. Casamento joined RiboGene as Chairman, President and CEO. He took the Company public and completed several major corporate collaborations including a merger with another public corporation to form Questcor Pharmaceuticals, where he held roles as Chairman, CEO and President.

He is a Director and Board member at Cortex Pharmaceuticals and SuperGen, and he is a registered pharmacist in New York and New Jersey . A graduate of Fordham University in New York City and Iona College in New Rochelle , New York , Mr. Casamento has a degree in Pharmacy and an MBA.